Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday.
A total of 106 patients with short-bowel syndrome (SBS) who also experienced intestinal failure and dependency on parenteral support (PS) at least three days per week took part in the evenly randomized double-blind trial, receiving treatment with 10mg glepaglutide either once or twice weekly, or a placebo.
